Dose-Response Association of CD8+ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer

#	Paper	IF	Citations
216	Dynamics of the Intratumoral Immune Response during Progression of High-Grade Serous Ovarian Cancer. **2018**, 20, 280-288		17
215	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. **2018**, 93, 307-320		14
214	Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8 T Cell Responses. **2018**, 9, 2968		14
213	Ovarian Cancer-Intrinsic Fatty Acid Synthase Prevents Anti-tumor Immunity by Disrupting Tumor-Infiltrating Dendritic Cells. **2018**, 9, 2927		45
212	Epithelial Tumors of the Ovary. **2018**, 1-128		
211	Utility of CD8 score by automated quantitative image analysis in head and neck squamous cell carcinoma. **2018**, 86, 278-287		23
210	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes. **2018**, 119, 1401-1409		100
209	Emerging Role and Future Directions of Immunotherapy in Advanced Ovarian Cancer. **2018**, 32, 1025-1039		9
208	The DNA damage response in immunotherapy and radiation. **2018**, 3, 527-533		18
207	Major clinical research advances in gynecologic cancer in 2017. **2018**, 29, e31		18
206	Regulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment. **2018**, 10,		54
205	Adoptive cell transfer using autologous tumor infiltrating lymphocytes in gynecologic malignancies. **2018**, 150, 361-369		18
204	Potent immunogenicity in BRCA1-mutated patients with high-grade serous ovarian carcinoma. **2018**, 22, 3979		28
203	T-cell Responses to "Hotspot" Mutations and Unique Neoantigens Expressed by Human Ovarian Cancers. **2018**, 24, 5562-5573		76
202	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. **2018**, 30, 515-524		10
201	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. **2018**, 4, 250-261		38
200	Interfaces of Malignant and Immunologic Clonal Dynamics in Ovarian Cancer. **2018**, 173, 1755-1769.e22		159

199	Role of tumor microenvironment in the pathobiology of ovarian cancer: Insights and therapeutic opportunities. **2018**, 7, 5047-5056		26
198	Ovarian Cancers: Genetic Abnormalities, Tumor Heterogeneity and Progression, Clonal Evolution and Cancer Stem Cells. **2018**, 5,		80
197	The Role of Intra-Tumoral Heterogeneity and Its Clinical Relevance in Epithelial Ovarian Cancer Recurrence and Metastasis. **2019**, 11,		20
196	Epithelial Tumors of the Ovary. **2019**, 841-966		6
195	Immune Heterogeneity Between Primary Tumors and Corresponding Metastatic Lesions and Response to Platinum Therapy in Primary Ovarian Cancer. **2019**, 11,		11
194	Tumor infiltrating lymphocytes can help to identify CD8+ tumor infiltrating lymphocytes and histopathologic subtypes of ovarian carcinoma. **2019**, 1246, 012033		
193	Lymphocyte-specific kinase expression is a prognostic indicator in ovarian cancer and correlates with a prominent B cell transcriptional signature. **2019**, 68, 1515-1526		8
192	Patients with BRCA mutated ovarian cancer may have fewer circulating MDSC and more peripheral CD8 T cells compared with women with BRCA wild-type disease during the early disease course. **2019**, 18, 3914-3924		3
191	Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. *JAMA Oncology*, **2019**, 5, 393-401	13.4	178
190	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. **2019**, 32, 1834-1846		21
189	Effect of an Integrated Payment System on the Direct Economic Burden and Readmission of Rural Cerebral Infarction Inpatients: Evidence from Anhui, China. **2019**, 16,		2
188	An international, phase III randomized trial in patients with mucinous epithelial ovarian cancer (mEOC/GOG 0241) with long-term follow-up: and experience of conducting a clinical trial in a rare gynecological tumor. **2019**, 153, 541-548		37
187	The Tumor Immune Microenvironment Drives a Prognostic Relevance That Correlates with Bladder Cancer Subtypes. **2019**, 7, 923-938		69
186	Neoantigens retention in patient derived xenograft models mediates autologous T cells activation in ovarian cancer. **2019**, 8, e1586042		12
185	Tumour infiltrating lymphocytes and PD-L1 expression as potential predictors of outcome in patients with malignant pleural mesothelioma. **2019**, 46, 2713-2720		11
184	Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. **2019**, 145, 1043-1053		27
183	Tumor infiltrating lymphocytes and homologous recombination deficiency are independently associated with improved survival in ovarian carcinoma. **2019**, 153, 217-222		13
182	Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. **2019**, 9, 17589		7

181	In Silico Methods for Studying T Cell Biology. **2019**, 342, 265-304	
180	Immunotherapies based on PD-1/PD-L1 pathway inhibitors in ovarian cancer treatment. **2019**, 195, 334-344	15
179	Genomic Applications in Ovarian Cancer. **2019**, 471-482	
178	Immune profiling and identification of prognostic immune-related risk factors in human ovarian cancer. **2019**, 8, e1535730	32
177	Development and validation of an immune prognostic signature for ovarian carcinoma. **2020**, 3, e1166	3
176	Tumour immune cell infiltration and survival after platinum-based chemotherapy in high-grade serous ovarian cancer subtypes: A gene expression-based computational study. **2020**, 51, 102602	44
175	Tumor Infiltrating Lymphocytes and CD8+ T Cell Subsets as Prognostic Markers in Patients with Surgically Treated Laryngeal Squamous Cell Carcinoma. **2020**, 14, 689-700	12
174	The hallmarks of ovarian cancer: Focus on angiogenesis and micro-environment and new models for their characterisation. **2020**, 15, 49-55	4
173	Three Genes Predict Prognosis in Microenvironment of Ovarian Cancer. **2020**, 11, 990	2
172	Th17-inducing autologous dendritic cell vaccination promotes antigen-specific cellular and humoral immunity in ovarian cancer patients. **2020**, 11, 5173	8
171	MiRNA505/NET1 Axis Acts as a CD8 T-TIL Regulator in Non-Small Cell Lung Cancer. **2020**, 13, 9785-9795	1
170	Investigating Patterns of Immune Interaction in Ovarian Cancer: Probing the O-glycoproteome by the Macrophage Galactose-Like C-type Lectin (MGL). **2020**, 12,	1
169	Are antiangiogenics a good ℚartnerℚfor immunotherapy in ovarian cancer?. **2020**, 23, 543-557	7
168	Integrated Analysis of Prognostic and Immune Associated Integrin Family in Ovarian Cancer. **2020**, 11, 705	8
167	Mutations in and differentially affect the tumor microenvironment and response to checkpoint blockade immunotherapy. **2021**, 1, 1188-1203	43
166	Immune Checkpoint Blockade in Gynecologic Cancers: State of Affairs. **2020**, 12,	6
165	MiRNA-340-5p mediates the functional and infiltrative promotion of tumor-infiltrating CD8 T lymphocytes in human diffuse large B cell lymphoma. **2020**, 39, 238	5
164	Prognostic impact of tumor-infiltrating lymphocytes in high grade serous ovarian cancer: a systematic review and meta-analysis. **2020**, 12, 1758835920967241	12

163	PD-L1 Expression and CD8+ Tumor-infiltrating Lymphocytes in Different Types of Tubo-ovarian Carcinoma and Their Prognostic Value in High-grade Serous Carcinoma. **2020**, 44, 1050-1060	12
162	Morphological and molecular heterogeneity of epithelial ovarian cancer: Therapeutic implications. **2020**, 15, 1-15	7
161	A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high-grade serous ovarian cancer. **2020**, 12, 94	6
160	Identification of serum cytokine clusters associated with outcomes in ovarian clear cell carcinoma. **2020**, 10, 18503	1
159	Association between physical activity and kidney stones based on dose-response analyses using restricted cubic splines. **2020**, 30, 1206-1211	0
158	Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer. **2021**, 77, 127-143	21
157	Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy. **2020**, 9,	8
156	Profound Functional Suppression of Tumor-Infiltrating T-Cells in Ovarian Cancer Patients Can Be Reversed Using PD-1-Blocking Antibodies or DARPin Proteins. **2020**, 2020, 7375947	2
155	Immunotherapy Advances for Epithelial Ovarian Cancer. **2020**, 12,	7
154	Hypoxia-Mediated Decrease of Ovarian Cancer Cells Reaction to Treatment: Significance for Chemo- and Immunotherapies. **2020**, 21,	7
153	Characterization of immunoreactivity with whole-slide imaging and digital analysis in high-grade serous ovarian cancer. **2020**, 42, 1010428320971404	3
152	Indoleamine 2, 3-Dioxygenase 1 and CD8 Expression Profiling Revealed an Immunological Subtype of Colon Cancer With a Poor Prognosis. **2020**, 10, 594098	2
151	Changes in the Tumor Immune Microenvironment during Disease Progression in Patients with Ovarian Cancer. **2020**, 12,	5
150	Comprehensive analysis of prognostic gene signatures based on immune infiltration of ovarian cancer. **2020**, 20, 1205	8
149	Integrated digital pathology and transcriptome analysis identifies molecular mediators of T-cell exclusion in ovarian cancer. **2020**, 11, 5583	25
148	Prognostic significance of baseline T cells, B cells and neutrophil-lymphocyte ratio (NLR) in recurrent ovarian cancer treated with chemotherapy. **2020**, 13, 59	3
147	Combined CCNE1 high-level amplification and overexpression is associated with unfavourable outcome in tubo-ovarian high-grade serous carcinoma. **2020**, 6, 252-262	16
146	Heterogeneity of immune microenvironment in ovarian cancer and its clinical significance: a retrospective study. **2020**, 9, 1760067	15

145   Prognostic gene expression signature for high-grade serous ovarian cancer. **2020**, 31, 1240-1250   37

144   Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy. **2020**, 52, 582-593   64

143   The Prognostic Value of Neutrophil-to-lymphocyte Ratio and Monocyte-to-lymphocyte Ratio in Metastatic Gastric Cancer Treated with Systemic Chemotherapy. **2020**, 11, 4205-4212   11

142   Molecular Heterogeneity of Endometrioid Ovarian Carcinoma: An Analysis of 166 Cases Using the Endometrial Cancer Subrogate Molecular Classification. **2020**, 44, 982-990   16

141   Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). **2020**, 26, 5411-5423   21

140   Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. **2020**, 123, 793-802   16

139   Ovarian Cancer, Cancer Stem Cells and Current Treatment Strategies: A Potential Role of Magmas in the Current Treatment Methods. **2020**, 9,   20

138   Lauren classification identifies distinct prognostic value and functional status of intratumoral CD8 T cells in gastric cancer. **2020**, 69, 1327-1336   13

137   RNA Immune Signatures from Pan-Cancer Analysis Are Prognostic for High-Grade Serous Ovarian Cancer and Other Female Cancers. **2020**, 12,   9

136   Sustained response to pembrolizumab without prior chemotherapy in high-grade serous ovarian carcinoma with mutation. **2020**, 33, 100600   5

135   Prognostic value of VISTA in solid tumours: a systematic review and meta-analysis. **2020**, 10, 2662   9

134   Th17 Cells and IL-17 As Novel Immune Targets in Ovarian Cancer Therapy. **2020**, 2020, 8797683   12

133   Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. **2020**, 53, 102659   26

132   Favorable prognostic impact of Natural Killer cells and T cells in high-grade serous ovarian carcinoma. **2020**, 59, 652-659   13

131   RNA-Seq-Based TCR Profiling Reveals Persistently Increased Intratumoral Clonality in Responders to Anti-PD-1 Therapy. **2020**, 10, 385   4

130   Combining measures of immune infiltration shows additive effect on survival prediction in high-grade serous ovarian carcinoma. **2020**, 122, 1803-1810   11

129   Current Ovarian Cancer Maintenance Strategies and Promising New Developments. **2021**, 12, 38-53   12

128   Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer. **2021**, 70, 1189-1202   2

127	Circulating CD14 HLA-DR monocytic cells as a biomarker for epithelial ovarian cancer progression. **2021**, 85, e13343	1
126	CXCL13 shapes immunoactive tumor microenvironment and enhances the efficacy of PD-1 checkpoint blockade in high-grade serous ovarian cancer. **2021**, 9,	24
125	Ovarian Cancer: Therapeutic Strategies to Overcome Immune Suppression. **2021**, 1330, 33-54	1
124	Indoleamine 2,3-dioxygenase upregulates PD-1 expression on ovarian tumor infiltrating CD8+ T cells via kynurenine activation of the aryl hydrocarbon receptor.	
123	Remission-Stage Ovarian Cancer Cell Vaccine with Cowpea Mosaic Virus Adjuvant Prevents Tumor Growth. **2021**, 13,	3
122	High-dimensional analysis of the adenosine pathway in high-grade serous ovarian cancer. **2021**, 9,	6
121	Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19-IL2 cures poorly immunogenic tumors when combined with radiotherapy. **2021**, 9,	6
120	PD-1 and PD-L1 expression on TILs in peritoneal metastases compared to ovarian tumor tissues and its associations with clinical outcome. **2021**, 11, 6400	1
119	The immune landscape during the tumorigenesis of cervical cancer. **2021**, 10, 2380-2395	2
118	Combination of Immune-Related Genomic Alterations Reveals Immune Characterization and Prediction of Different Prognostic Risks in Ovarian Cancer. **2021**, 9, 653357	
117	HE4 Overexpression by Ovarian Cancer Promotes a Suppressive Tumor Immune Microenvironment and Enhanced Tumor and Macrophage PD-L1 Expression. **2021**, 206, 2478-2488	1
116	IDO1 Expression in Ovarian Cancer Induces PD-1 in T Cells Aryl Hydrocarbon Receptor Activation. **2021**, 12, 678999	7
115	Somatic genomic rearrangements in human leucocyte antigens region in solid ovarian tumors. **2021**, 37, 105-116	
114	T-Cell Receptor Therapy in the Treatment of Ovarian Cancer: A Mini Review. **2021**, 12, 672502	1
113	Tumor genomic, transcriptomic, and immune profiling characterizes differential response to first-line platinum chemotherapy in high grade serous ovarian cancer. **2021**, 10, 3045-3058	6
112	Assessment of Immunological Features in Muscle-Invasive Bladder Cancer Prognosis Using Ensemble Learning. **2021**, 13,	5
111	Statistical framework for studying the spatial architecture of the tumor immune microenvironment.	2
110	A Keratin 7 and E-Cadherin Signature Is Highly Predictive of Tubo-Ovarian High-Grade Serous Carcinoma Prognosis. **2021**, 22,	2

109	Dual G9A and EZH2 inhibition stimulates an anti-tumour immune response in ovarian high-grade serous carcinoma.	
108	Identification of a Prognostic Signature for Ovarian Cancer Based on the Microenvironment Genes. **2021**, 12, 680413	6
107	Spatial cytotoxic and memory T cells in tumor predict superior survival outcomes in patients with high-grade serous ovarian cancer. **2021**, 10, 3905-3918	3
106	Molecular Analysis of an Abdominal Wall Cesarean Section Endometrioid Carcinoma. **2021**, 10668969211018262	
105	Quantitative Multiplex Immunofluorescence Evaluation of the Tumor Microenvironment in Pretreatment Tumors of Patients with Metastatic Breast Cancer and Serous Ovarian Carcinoma Treated with Liposomal Eribulin. **2021**, 39, 466-472	
104	Association of CLDN6 and CLDN10 With Immune Microenvironment in Ovarian Cancer: A Study of the Claudin Family. **2021**, 12, 595436	1
103	VISTA: A Promising Target for Cancer Immunotherapy?. **2021**, 10, 185-200	5
102	Immunotherapy in rare ovarian cancer. **2021**, 33, 447-456	2
101	Predicting Panel of Metabolism and Immune-Related Genes for the Prognosis of Human Ovarian Cancer. **2021**, 9, 690542	2
100	Cell-autonomous inflammation of BRCA1-deficient ovarian cancers drives both tumor-intrinsic immunoreactivity and immune resistance via STING. **2021**, 36, 109412	12
99	Programmed death ligand-1 and CD8 tumor-infiltrating lymphocytes (TILs) as prognostic predictors in ovarian high-grade serous carcinoma (HGSC). **2021**, 33, 16	0
98	Prognostic significance of T cells, PD-L1 immune checkpoint and tumour associated macrophages in clear cell carcinoma of the ovary. **2021**, 162, 421-430	1
97	Application of Immunoprofiling Using Multiplexed Immunofluorescence Staining Identifies the Prognosis of Patients with High-Grade Serous Ovarian Cancer. **2021**, 22,	0
96	SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in high-grade serous ovarian cancer. **2021**, 6,	1
95	Personalized models of heterogeneous 3D epithelial tumor microenvironments: Ovarian cancer as a model. **2021**, 132, 401-420	1
94	Upregulated Expression of CYBRD1 Predicts Poor Prognosis of Patients with Ovarian Cancer. **2021**, 2021, 7548406	2
93	Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma.	1
92	Effect of MAP3K8 on Prognosis and Tumor-Related Inflammation in Renal Clear Cell Carcinoma. **2021**, 12, 674613	1

91	Unraveling Tumor-Immune Heterogeneity in Advanced Ovarian Cancer Uncovers Immunogenic Effect of Chemotherapy.	2
90	Prognostic significance of tumor genotypes and CD8+ infiltrates in stage I-III colorectal cancer. **2018**, 9, 35623-35638	12
89	Clonality and antigen-specific responses shape the prognostic effects of tumor-infiltrating T cells in ovarian cancer. **2020**, 11, 2669-2683	2
88	Current and future immunotherapy approaches in ovarian cancer. **2020**, 8, 1714	10
87	Poor Lymphocyte Infiltration to Primary Tumors in Acral Lentiginous Melanoma and Mucosal Melanoma Compared to Cutaneous Melanoma. **2020**, 10, 524700	6
86	A multiomics comparison between endometrial cancer and serous ovarian cancer. **2020**, 8, e8347	3
85	DNA Methylation Profiles of Ovarian Clear Cell Carcinoma. **2021**,	2
84	Immunological configuration of ovarian carcinoma: features and impact on disease outcome. **2021**, 9,	4
83	Epithelial Tumors of the Ovary. **2018**, 1-128	
82	A cell-of-origin epigenetic tracer reveals clinically distinct subtypes of high grade serous ovarian cancer.	
81	A Single-Cell Immune Atlas of Triple Negative Breast Cancer Reveals Novel Immune Cell Subsets.	2
80	Identification of Immunological Features Enables Survival Prediction of Muscle-Invasive Bladder Cancer Patients Using Machine Learning.	1
79	SLFN11 captures cancer-immunity interactions associated with platinum sensitivity in ovarian cancer.	
78	CXCR6 by increasing retention of memory CD8 T cells in the ovarian tumor microenvironment promotes immunosurveillance and control of ovarian cancer.	
77	PD-L1 in Combination with CD8TIL and HIF-1□ are Promising Prognosis Predictors of Head and Neck Squamous Cell Carcinoma. **2020**, 12, 13233-13239	2
76	Myeloid antigen-presenting cell niches sustain antitumor T□cells and license PD-1 blockade via CD28 costimulation. **2021**,	3
75	Identification of Immune-Related Key Genes in Ovarian Cancer Based on WGCNA. **2021**, 12, 760225	3
74	Characterizing Endocrine Status, Tumor Hypoxia and Immunogenicity for Therapy Success in Epithelial Ovarian Cancer. **2021**, 12, 772349	0

73	Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer.. **2022**, 119,	5
72	Safety and efficacy of dendritic cell-based immunotherapy DCVAC/OvCa added to first-line chemotherapy (carboplatin plus paclitaxel) for epithelial ovarian cancer: a phase 2, open-label, multicenter, randomized trial.. **2022**, 10,	1
71	The Evolution of Ovarian Carcinoma Subclassification.. **2022**, 14,	5
70	Immune-related gene expression signatures: A step forward in the stratification of patients with ovarian clear cell carcinoma.. **2021**,	
69	Integrated analysis of prognostic immune-related genes in the tumor microenvironment of ovarian cancer.. **2022**, 10, 91	0
68	Understanding the impact of chemotherapy on the immune landscape of high-grade serous ovarian cancer.. **2022**, 39, 100926	1
67	Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities.. **2022**, 10,	0
66	Clinical significance of CD8-positive lymphocytes on tumor cell clusters of ascites cell block in ovarian high-grade serous carcinoma.. **2022**,	
65	Subtyping of high grade serous ovarian carcinoma: histopathological and immunohistochemical approach.. **2022**, 34, 6	
64	Dual G9A/EZH2 inhibition stimulates anti-tumour immune response in ovarian high grade serous carcinoma.. **2022**,	1
63	Validated biomarker assays confirm ARID1A loss is confounded with MMR deficiency, CD8 TIL infiltration, and provides no independent prognostic value in endometriosis-associated ovarian carcinomas.. **2021**,	3
62	A prognostic classification based on the International Association for the Study of Lung Cancer histologic grading and immunoscore in KRAS-mutant invasive non-mucinous adenocarcinoma.. **2022**,	2
61	Tumor immune cell clustering and its association with survival in African American women with ovarian cancer.. **2022**, 18, e1009900	1
60	Adoptive cell therapy in gynecologic cancers: A systematic review and meta-analysis.. **2022**,	0
59	Biological Role of Tumor/Stromal CXCR4-CXCL12-CXCR7 in MITO16A/MaNGO-OV2 Advanced Ovarian Cancer Patients.. **2022**, 14,	0
58	The STING pathway: Therapeutic vulnerabilities in ovarian cancer.. **2022**,	0
57	Predicting Response to Anthracyclines in Ovarian Cancer.. **2022**, 19,	
56	Barriers to Immunotherapy in Ovarian Cancer: Metabolic, Genomic, and Immune Perturbations in the Tumour Microenvironment.. **2021**, 13,	1

55   Significance of CD47 and Its Association With Tumor Immune Microenvironment Heterogeneity in Ovarian Cancer.. **2021**, 12, 768115   0

54   Prognostic markers of inflammation in endometrioid and clear cell ovarian cancer.. **2022**,

53   Image_1.TIF. **2020**,

52   Image_2.TIF. **2020**,

51   Image_3.TIF. **2020**,

50   Image_4.TIF. **2020**,

49   Table_1.docx. **2020**,

48   Table_2.docx. **2020**,

47   Data_Sheet_1.docx. **2018**,

46   DataSheet_1.pdf. **2020**,

45   Image_1.pdf. **2020**,

44   Table_1.pdf. **2020**,

43   Image_1.jpeg. **2020**,

42   Image_2.jpeg. **2020**,

41   Tumor FAK orchestrates immunosuppression in ovarian cancer via the CD155/TIGIT axis.. **2022**, 119, e2117065119   1

40   Racial differences in the tumor immune landscape and survival of women with high-grade serous ovarian carcinoma.. **2022**,   0

39   High expression of RIPK2 is associated with Taxol resistance in serous ovarian cancer.. **2022**, 15, 48   1

38   A Preliminary Exploration Using Imaging Methods to Predict the Possibility of the Recurrence of Serous Ovarian Cancer in Patients Undergoing Total Resection.. **2022**, 12, 754067

| 37 | Shifting the Soil: Metformin Treatment Decreases the Protumorigenic Tumor Microenvironment in Epithelial Ovarian Cancer.. **2022**, 14, | 1 |

| 36 | The Role of Cancer-Associated Fibroblasts in Ovarian Cancer. **2022**, 14, 2637 | 4 |

| 35 | Identification of CD8+ T Cell Related Biomarkers in Ovarian Cancer. 13, | |

| 34 | The Association between Daily Dietary Intake of Riboflavin and Lung Function Impairment Related with Dibutyl Phthalate Exposure and the Possible Mechanism. **2022**, 14, 2282 | 0 |

| 33 | Programmed Death Ligand 1 (PD-L1) Expression and CD8+ Tumor-infiltrating Lymphocyte-based Tumor Immune Microenvironment Classification in Gynecologic Carcinosarcoma: Prognostic Impact and Implications for Therapy. **16**, Publish Ahead of Print, | |

| 32 | Identification and Validation of the Diagnostic Characteristic Genes of Ovarian Cancer by Bioinformatics and Machine Learning. 13, | 1 |

| 31 | Association between childhood friendship and cognitive ageing trajectory in later life: evidence from the China Health and Retirement Longitudinal Study (CHARLS). **2022**, 22, | 1 |

| 30 | Development and Validation of a Hypoxia - Related Prognostic Model for Ovarian Cancer. **2022**, 17, | |

| 29 | Prognostic Characteristics of Immune-Related Genes and the Related Regulatory Axis in Patients With Stage N+M0 Breast Cancer. 12, | |

| 28 | KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian Cancer. OF1-OF11 | |

| 27 | PTEN and BRCA1 tumor suppressor loss associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in a murine model of ovarian cancer. | 0 |

| 26 | Ovarialkarzinom: Immuntherapie, quo vadis?. | |

| 25 | The m6A-Related Long Noncoding RNA Signature Predicts Prognosis and Indicates Tumor Immune Infiltration in Ovarian Cancer. **2022**, 14, 4056 | 0 |

| 24 | Phosphoserine phosphatase as an indicator for survival through potentially influencing the infiltration levels of immune cells in neuroblastoma. 10, | |

| 23 | Prognostic and Predictive Role of Tumor-Infiltrating Lymphocytes (TILs) in Ovarian Cancer. **2022**, 14, 4344 | 0 |

| 22 | Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation. | 2 |

| 21 | Loss of Major Histocompatibility Complex Class I, CD8+ Tumor-infiltrating Lymphocytes, and PD-L1 Expression in Ovarian Clear Cell Carcinoma. Publish Ahead of Print, | 0 |

| 20 | The genomic landscape of recurrent ovarian high grade serous carcinoma: the BriTROC-1 study. | 0 |

19	Tumor-Infiltrating Lymphocytes (TILs) in Epithelial Ovarian Cancer: Heterogeneity, Prognostic Impact, and Relationship with Immune Checkpoints. **2022**, 14, 5332	1
18	Increased FOXJ1 protein expression is associated with improved overall survival in high-grade serous ovarian carcinoma: an Ovarian Tumor Tissue Analysis Consortium Study.	0
17	Integration of local and systemic immunity in ovarian cancer: Implications for immunotherapy. 13,	1
16	The prognostic significance of CXCR4 and SDF-1 in differentiated thyroid cancer depends on CD8+ density. **2022**, 22,	0
15	Dynamic Changes in the Extracellular Matrix in Primary, Metastatic, and Recurrent Ovarian Cancers. **2022**, 11, 3769	0
14	Multi-omics-based analysis of high grade serous ovarian cancer subtypes reveals distinct molecular processes linked to patient prognosis.	0
13	A novel defined risk signature of endoplasmic reticulum stress-related genes for predicting the prognosis and immune infiltration status of ovarian cancer. **2023**, 24, 64-77	0
12	Prognostic impact of tumor size on isolated hepatocellular carcinoma without vascular invasion may have age variance. 9,	0
11	BRCA1 expression, its correlation with clinicopathological features and response to neoadjuvant chemotherapy in high grade serous ovarian cancer from an Indian centre.	0
10	Multiparameter single-cell proteomic technologies give new insights into the biology of ovarian tumors.	0
9	Pan-cancer analyses reveal IGSF10 as an immunological and prognostic biomarker. 13,	0
8	Predictors of residual disease after debulking surgery in advanced stage ovarian cancer. 13,	0
7	Discordance of PD-L1 expression in primary and metastatic ovarian high-grade serous carcinoma and its correlation with CD8 + tumor-infiltrating lymphocytes and patient prognosis. **2023**, 482, 755-766	0
6	The Interaction between Intratumoral Microbiome and Immunity Is Related to the Prognosis of Ovarian Cancer. **2023**, 11,	0
5	Machine learning-based integration develops an immune-related risk model for predicting prognosis of high-grade serous ovarian cancer and providing therapeutic strategies. 14,	0
4	Deep Learning Provides a New Magnetic Resonance Imaging-Based Prognostic Biomarker for Recurrence Prediction in High-Grade Serous Ovarian Cancer. **2023**, 13, 748	0
3	Evaluation of multiple immune cells and patient outcomes in esophageal squamous cell carcinoma. 14,	0
2	p53 and ovarian carcinoma survival: an Ovarian Tumor Tissue Analysis consortium study. **2023**, 9, 208-222	0

1 Cancer cell genotype associated tumor immune microenvironment exhibits differential response to therapeutic STING pathway activation in high-grade serous ovarian cancer. **2023**, 11, e006170

O